在高脂肪饮食中的卵巢切除小鼠中,GPR30选择性激素G-1诱导了胰岛素耐药性及其机制
Congcong Lu1, Da Liu1, Min Li1
1Department of Cardiology, The First Hospital of Hebei Medical University, 89 Donggang Road, Shijiazhuang, 050000, Hebei, China.
概括
雌激素受体激动剂G-1降低了体重,但恶化了胰岛素抵抗,并在高脂肪饮食中的小鼠中引起心脏损伤. 在临床使用之前需要进行进一步的安全性研究.
科学领域:
- 内分泌学 在内分泌学.
- 代谢综合征是代谢综合征的一种.
- 心血管研究研究心血管研究
背景情况:
- 雌激素受体激动剂G-1影响葡萄糖和脂质代谢.
- 以前的研究表明G-1在代谢过程中的调节作用.
研究的目的:
- 研究G-1对心脏代谢综合征和肥胖症的影响.
- 评估G-1在高脂肪饮食 (HFD) 下对心脏功能和胰岛素信号传递的影响.
主要方法:
- 在HFD的卵巢切除小鼠被用G-1治疗.
- 使用心肌细胞胰岛素耐药性模型.
- 估计的体重,血糖,血清胰岛素,心脏功能,纤维化和分子标记 (p-AMPK,p-AKT,GLUT4).
主要成果:
- G-1 减轻了体重,但增加了血糖和胰岛素抵抗.
- 观察到心肌损伤,包括心肌细胞障碍,糖原积累和心脏纤维化.
- 通过AMPK/TBC1D1通路,G-1增强了葡萄糖生成并抑制了GLUT4转位.
结论:
- G-1的减肥益处被诱导的胰岛素抵抗和心脏功能障碍所抵消.
- 在考虑G-1用于临床应用之前,全面的安全性和有效性评估至关重要.
相关概念视频
Glucagon-like Receptor Agonists
319
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319
Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
GPCRs Regulate Adenylyl Cylase Activity
5.5K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.5K


